中红医疗
(300981)
| 流通市值：54.55亿 | | | 总市值：59.53亿 |
| 流通股本：3.93亿 | | | 总股本：4.29亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,237,534,880.54 | 629,149,972.58 | 2,456,650,714.86 | 1,838,289,686.09 |
| 营业收入 | 1,237,534,880.54 | 629,149,972.58 | 2,456,650,714.86 | 1,838,289,686.09 |
| 二、营业总成本 | 1,238,841,258.3 | 611,325,794.71 | 2,368,710,307.73 | 1,796,999,850.39 |
| 营业成本 | 1,096,943,901.11 | 545,104,981.95 | 2,128,183,526.9 | 1,601,889,294.16 |
| 税金及附加 | 12,437,666.35 | 5,864,876.77 | 19,187,352.34 | 13,940,483.58 |
| 销售费用 | 61,250,919.04 | 28,905,695.56 | 117,057,879.84 | 88,864,953.67 |
| 管理费用 | 62,437,866.29 | 29,593,781.35 | 126,638,932.82 | 78,821,539.31 |
| 研发费用 | 23,972,004.69 | 11,499,945.08 | 49,703,810.59 | 35,548,218.01 |
| 财务费用 | -18,201,099.18 | -9,643,486 | -72,061,194.76 | -22,064,638.34 |
| 其中:利息费用 | 12,267,763.22 | 5,586,848.87 | 24,090,843.34 | 17,827,071.93 |
| 其中:利息收入 | 29,864,341.96 | 13,831,802.96 | 67,846,377.81 | 52,601,631.1 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 20,347,303.14 | 6,910,640.29 | 48,107,894.49 | 37,059,013.44 |
| 加:投资收益 | 4,229,774.75 | 963,156.71 | 11,020,084.83 | 13,338,656.88 |
| 净敞口套期收益 | 0 | - | 0 | - |
| 资产处置收益 | -792,071.2 | -2,761.06 | 852,573.04 | -2,322.57 |
| 资产减值损失(新) | -17,222,220.49 | -3,912,942.94 | -228,888,328 | -42,547,150.18 |
| 信用减值损失(新) | -5,093,642.09 | -456,307.24 | -5,062,697.93 | -1,707,513.1 |
| 其他收益 | 4,987,971.08 | 1,348,556.76 | 20,292,700.71 | 15,854,350.2 |
| 四、营业利润 | 5,150,737.43 | 22,674,520.39 | -65,737,365.73 | 63,284,870.37 |
| 加:营业外收入 | 1,801,029.8 | 577,008.37 | 1,126,657.52 | 171,870.99 |
| 减:营业外支出 | 789,290.38 | 180,731.04 | 2,292,734.6 | 1,116,922.26 |
| 五、利润总额 | 6,162,476.85 | 23,070,797.72 | -66,903,442.81 | 62,339,819.1 |
| 减:所得税费用 | 1,984,183.2 | 3,723,636.47 | 18,926,992.5 | 7,356,176.66 |
| 六、净利润 | 4,178,293.65 | 19,347,161.25 | -85,830,435.31 | 54,983,642.44 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 4,178,293.65 | 19,347,161.25 | -85,830,435.31 | 54,983,642.44 |
| 终止经营净利润 | 0 | - | 0 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 5,742,934.2 | 18,921,091.71 | -87,128,895.94 | 51,032,305.48 |
| 少数股东损益 | -1,564,640.55 | 426,069.54 | 1,298,460.63 | 3,951,336.96 |
| 扣除非经常损益后的净利润 | -13,174,490.58 | 11,371,210.65 | -143,463,298.44 | -183,696.44 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | 0.05 | -0.22 | 0.13 |
| (二)稀释每股收益 | 0.01 | 0.05 | -0.22 | 0.13 |
| 八、其他综合收益 | -635,986.53 | -253,697.08 | -2,540,792.49 | 499,870.01 |
| 归属于母公司股东的其他综合收益 | -635,986.53 | -253,697.08 | -2,540,792.49 | 499,870.01 |
| 九、综合收益总额 | 3,542,307.12 | 19,093,464.17 | -88,371,227.8 | 55,483,512.45 |
| 归属于母公司股东的综合收益总额 | 5,106,947.67 | 18,667,394.63 | -89,669,688.43 | 51,532,175.49 |
| 归属于少数股东的综合收益总额 | -1,564,640.55 | 426,069.54 | 1,298,460.63 | 3,951,336.96 |
| 公告日期 | 2025-08-28 | 2025-04-23 | 2025-04-23 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |